Pfizer-BioNTech, Moderna, Janssen vaccines highly effective for preventing COVID-19-linked hospitalization
TUESDAY, Aug. 10, 2021 (HealthDay News) — The Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines are highly effective for preventing COVID-19-associated hospitalization among older adults in the United States, according to research published in the Aug. 6 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Heidi L. Moline, M.D., from the CDC COVID-19 Response Team, and colleagues examined the real-world effectiveness of the three currently authorized COVID-19 vaccines among individuals aged 65 years and older during Feb. 1 to April 30, 2021. Data from 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network were analyzed with vaccination coverage data.
The researchers found that the effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96, 96, and 84 percent for the Pfizer-BioNTech, Moderna, and Janssen vaccine products, respectively, among adults aged 65 to 74 years. Among adults aged 75 years or older, the effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 91, 96, and 85 percent, respectively.
“These findings provide additional evidence that available vaccines are highly effective in preventing COVID-19-associated hospitalizations and demonstrate that performance of COVID-19 vaccines can be assessed using existing disease surveillance and immunization data,” the authors write. “Efforts to increase vaccination coverage are critical to reducing the risk for COVID-19-related hospitalization, particularly in older adults.”
Several authors disclosed financial ties to the pharmaceutical industry.
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
Trends Reported in Vaccination Coverage for Adolescents for 2025
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD
NOACs Linked to Slower Cognitive Decline in Patients With A-Fib, Alzheimer Disease
Intensive BP Lowering Reduces Recurrent Stroke After Intracerebral Hemorrhage
Acute Myeloid Leukemia Increasingly Impacting Older Adults Globally